Gastrointestinal stromal tumour

Research output: Contribution to journalArticle

407 Citations (Scopus)

Abstract

Gastrointestinal stromal tumours are the most common mesenchymal neoplasm of the gastrointestinal tract and are highly resistant to conventional chemotherapy and radiotherapy. Such tumours usually have activating mutations in either KIT (75-80%) or PDGFRA (5-10%), two closely related receptor tyrosine kinases. These mutations lead to ligand-independent activation and signal transduction mediated by constitutively activated KIT or PDGFRA. Targeting these activated proteins with imatinib mesylate, a small-molecule kinase inhibitor, has proven useful in the treatment of recurrent or metastatic gastrointestinal stromal tumours and is now being tested as an adjuvant or neoadjuvant. However, resistance to imatinib is a growing problem and other targeted therapeutics such as sunitinib are available. The important interplay between the molecular genetics of gastrontestinal stromal tumour and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumours.

Original languageEnglish (US)
Pages (from-to)1731-1741
Number of pages11
JournalLancet
Volume369
Issue number9574
DOIs
StatePublished - May 19 2007

Fingerprint

Gastrointestinal Stromal Tumors
Neoplasms
Mutation
Receptor Protein-Tyrosine Kinases
Protein Transport
Therapeutics
Gastrointestinal Tract
Molecular Biology
Signal Transduction
Phosphotransferases
Radiotherapy
Ligands
Drug Therapy
Imatinib Mesylate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gastrointestinal stromal tumour. / Rubin, Brian P.; Heinrich, Michael; Corless, Christopher.

In: Lancet, Vol. 369, No. 9574, 19.05.2007, p. 1731-1741.

Research output: Contribution to journalArticle

Rubin, Brian P. ; Heinrich, Michael ; Corless, Christopher. / Gastrointestinal stromal tumour. In: Lancet. 2007 ; Vol. 369, No. 9574. pp. 1731-1741.
@article{981192aeb5c142ad9063e3f3bdd07082,
title = "Gastrointestinal stromal tumour",
abstract = "Gastrointestinal stromal tumours are the most common mesenchymal neoplasm of the gastrointestinal tract and are highly resistant to conventional chemotherapy and radiotherapy. Such tumours usually have activating mutations in either KIT (75-80{\%}) or PDGFRA (5-10{\%}), two closely related receptor tyrosine kinases. These mutations lead to ligand-independent activation and signal transduction mediated by constitutively activated KIT or PDGFRA. Targeting these activated proteins with imatinib mesylate, a small-molecule kinase inhibitor, has proven useful in the treatment of recurrent or metastatic gastrointestinal stromal tumours and is now being tested as an adjuvant or neoadjuvant. However, resistance to imatinib is a growing problem and other targeted therapeutics such as sunitinib are available. The important interplay between the molecular genetics of gastrontestinal stromal tumour and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumours.",
author = "Rubin, {Brian P.} and Michael Heinrich and Christopher Corless",
year = "2007",
month = "5",
day = "19",
doi = "10.1016/S0140-6736(07)60780-6",
language = "English (US)",
volume = "369",
pages = "1731--1741",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9574",

}

TY - JOUR

T1 - Gastrointestinal stromal tumour

AU - Rubin, Brian P.

AU - Heinrich, Michael

AU - Corless, Christopher

PY - 2007/5/19

Y1 - 2007/5/19

N2 - Gastrointestinal stromal tumours are the most common mesenchymal neoplasm of the gastrointestinal tract and are highly resistant to conventional chemotherapy and radiotherapy. Such tumours usually have activating mutations in either KIT (75-80%) or PDGFRA (5-10%), two closely related receptor tyrosine kinases. These mutations lead to ligand-independent activation and signal transduction mediated by constitutively activated KIT or PDGFRA. Targeting these activated proteins with imatinib mesylate, a small-molecule kinase inhibitor, has proven useful in the treatment of recurrent or metastatic gastrointestinal stromal tumours and is now being tested as an adjuvant or neoadjuvant. However, resistance to imatinib is a growing problem and other targeted therapeutics such as sunitinib are available. The important interplay between the molecular genetics of gastrontestinal stromal tumour and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumours.

AB - Gastrointestinal stromal tumours are the most common mesenchymal neoplasm of the gastrointestinal tract and are highly resistant to conventional chemotherapy and radiotherapy. Such tumours usually have activating mutations in either KIT (75-80%) or PDGFRA (5-10%), two closely related receptor tyrosine kinases. These mutations lead to ligand-independent activation and signal transduction mediated by constitutively activated KIT or PDGFRA. Targeting these activated proteins with imatinib mesylate, a small-molecule kinase inhibitor, has proven useful in the treatment of recurrent or metastatic gastrointestinal stromal tumours and is now being tested as an adjuvant or neoadjuvant. However, resistance to imatinib is a growing problem and other targeted therapeutics such as sunitinib are available. The important interplay between the molecular genetics of gastrontestinal stromal tumour and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumours.

UR - http://www.scopus.com/inward/record.url?scp=34249018869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249018869&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(07)60780-6

DO - 10.1016/S0140-6736(07)60780-6

M3 - Article

C2 - 17512858

AN - SCOPUS:34249018869

VL - 369

SP - 1731

EP - 1741

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9574

ER -